GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRhythm Technologies Inc (NAS:IRTC) » Definitions » Cash Conversion Cycle

iRhythm Technologies (iRhythm Technologies) Cash Conversion Cycle

: 53.45 (As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

iRhythm Technologies's Days Sales Outstanding for the three months ended in Dec. 2023 was 38.41.
iRhythm Technologies's Days Inventory for the three months ended in Dec. 2023 was 27.95.
iRhythm Technologies's Days Payable for the three months ended in Dec. 2023 was 12.91.
Therefore, iRhythm Technologies's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 53.45.


iRhythm Technologies Cash Conversion Cycle Historical Data

The historical data trend for iRhythm Technologies's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iRhythm Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.75 28.57 44.36 53.24 59.49

iRhythm Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.51 58.91 53.77 51.96 53.45

Competitive Comparison

For the Medical Devices subindustry, iRhythm Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iRhythm Technologies Cash Conversion Cycle Distribution

For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Technologies's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where iRhythm Technologies's Cash Conversion Cycle falls into.



iRhythm Technologies Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

iRhythm Technologies's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=41.27+33.04-14.82
=59.49

iRhythm Technologies's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=38.41+27.95-12.91
=53.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iRhythm Technologies  (NAS:IRTC) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


iRhythm Technologies Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of iRhythm Technologies's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


iRhythm Technologies (iRhythm Technologies) Business Description

Traded in Other Exchanges
Address
699 8th Street, Suite 600, San Francisco, CA, USA, 94103
iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio include ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for up to 14 consecutive days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.
Executives
Daniel G. Wilson officer: EVP, Strategy Corp Dev Inv Rel 699 8TH STREET, SUITE 600, SAN FRANCISCO CA 94103
Patrick Michael Murphy officer: CLO & EVP RA/QA MrktAcs & Gov 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Mervin Smith officer: EVP Strategic Business Ops C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Marc W. Rosenbaum officer: Chief Accounting Officer 7475 LUSK BLVD., SAN DIEGO CA 92121
Brice Bobzien officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Chad Patterson officer: Chief Commercial Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Minang Turakhia officer: EVP, CMO & CSO C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Quentin S. Blackford director, officer: President and CEO 7475 LUSK BLVD., SAN DIEGO CA 92121
Mojdeh Poul director 3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST PAUL MN 55144-1000
Brian B Yoor director 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064
Mark J. Day officer: EVP, Research & Development C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Douglas Devine officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH STREET, SUITE 600, SAN FRANCISCO CA 94103
Bairey Merz Cathleen Noel director 16664 CUMBRE VERDE COURT, PACIFIC PALISADES CA 90272
Reyna M Fernandez officer: EVP, Chief HR Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Sumi Shrishrimal officer: EVP, Chief Risk Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121

iRhythm Technologies (iRhythm Technologies) Headlines

From GuruFocus